US PTAB IP Litigation
8,722 annotated decisions
Page 190 of 364 · 8,722 total
patent terminated or settled · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
Liberty Energy and U.S. Well Services have settled their dispute over a modular switchgear patent, filing a joint motion to terminate the pending IPR.
patent terminated or settled · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
Liberty Energy and Liberty Oilfield Services entered a confidential settlement with U.S. Well Services, filing a joint request to keep the agreement private and to terminate the IPR covering a modular switchgear patent for electric oilfield equipment.
patent · Nov 20, 2024
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
· IPR2025-00201
Liberty Mutual filed a joint motion to terminate its IPR against Intellectual Ventures I’s patent 7,949,785.
patent terminated or settled · Nov 20, 2024
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
· IPR2025-00201
Liberty Mutual and patent‑holder Intellectual Ventures have settled their dispute over U.S. Patent 7,949,785 and jointly moved to terminate the pending IPR. The motion cites 35 U.S.C. § 317(a) and argues the proceeding is at an early stage with no merits decision.
patent · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
U.S. Well Services seeks Director Review to overturn the PTAB Board’s decision to institute an IPR on its hydraulic fracturing patent, arguing the Board misapplied Fintiv discretionary‑denial factors.
patent terminated or settled · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
Liberty Energy and U.S. Well Services settled their IPR dispute over patent 11,208,878, resulting in a joint motion to terminate the proceeding. The Board granted termination and kept the settlement confidential.
patent terminated or settled · Nov 20, 2024
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
· IPR2025-00200
Liberty Mutual and Intellectual Ventures settled their inter partes review disputes before any trial, leading the Board to terminate the three IPRs. The settlement agreements were treated as confidential business information.
patent instituted · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
The USPTO Director denied Liberty Energy’s request for a review of the institution decision on U.S. Patent 11,208,878, leaving the patent’s institution intact.
patent denied · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
The PTAB denied U.S. Well Services’ request to file new Director Review submissions in IPR2025‑00139, leaving the institution of the proceeding intact. The dispute centers on alleged violations of a Sotera stipulation by the petitioners in parallel district‑court litigation.
patent · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
Liberty Energy and Liberty Oilfield Services filed a detailed response defending the institution of IPR2025‑00139 against U.S. Well Services’ request for a Director’s discretionary denial. The brief leans heavily on Fintiv precedent and argues that the Board’s factual findings are correct and that the patent’s claims remain vulnerable to three prior‑art combinations.
patent · Nov 20, 2024
Luxottica of America Inc. et al. v.E-Vision Smart Optics, Inc.
· IPR2025-00216
Luxottica has filed an IPR petition seeking to invalidate all 20 claims of e‑Vision’s Bluetooth‑enabled smart‑eyewear patent, arguing the claims are obvious over multiple prior‑art references including Thiel, Jannard‑740 and Apple’s Siri technology.
patent · Nov 20, 2024
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
· IPR2025-00200
Liberty Mutual and Comerica have filed an IPR petition seeking cancellation of all 37 claims of Intellectual Ventures' 722 patent on the ground of obviousness over prior‑art event‑notification systems. The petition relies on expert testimony and argues that discretionary denial is unwarranted.
patent · Nov 20, 2024
Samsung Bioepis Co., Ltd. v.Regeneron Pharmaceuticals, Inc.
· IPR2025-00176
Samsung Bioepis has filed an IPR petition challenging 48 claims of Regeneron’s anti‑VEGF ophthalmic formulation patent, arguing the claims are obvious over prior‑art formulations and presentation data.
patent · Nov 20, 2024
Liberty Mutual Insurance Company et al. v.Intellectual Ventures II
· IPR2025-00202
Liberty Mutual has filed an IPR petition seeking to invalidate all 27 claims of Intellectual Ventures' 844 patent on the basis of obviousness. The petition argues that the examiner never considered key prior art and that discretionary denial is inappropriate.
patent · Nov 20, 2024
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
· IPR2025-00201
Liberty Mutual and Comerica petition the PTAB to invalidate 63 claims of IV’s ‘Secure Virtual Community Network System’ patent, arguing the claims are obvious over Mehta and RFC‑1383. The petition also argues that discretionary denial is inappropriate.
patent · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
Liberty Energy has filed an IPR petition seeking to invalidate ten claims of U.S. Patent 11,208,878 covering a modular switchgear system for oilfield fracturing equipment, arguing obviousness over multiple prior‑art references.
patent instituted · Nov 20, 2024
Luxottica of America Inc. et al. v.E-Vision Smart Optics, Inc.
· IPR2025-00216
The PTAB granted institution for Luxottica against E-Vision's electronic eyewear patent (11487138), finding a reasonable likelihood of unpatentability based on obviousness grounds using prior art like Thiel and Gruber.
patent denied · Nov 20, 2024
Samsung Bioepis Co., Ltd. v.Regeneron Pharmaceuticals, Inc.
· IPR2025-00176
Samsung Bioepis sought to invalidate numerous claims of Regeneron Pharmaceuticals' ophthalmic formulations using grounds of obviousness (103). The PTAB denied institution based on a holistic Fintiv analysis, citing significant overlap with ongoing district court and MDL proceedings.
patent instituted · Nov 20, 2024
Liberty Energy Inc. et al. v.U.S. Well Services, LLC
· IPR2025-00139
The PTAB granted institution for an IPR challenging claims 1-10 of U.S. Well Services' patent '878, focusing on hydraulic fracturing systems and power distribution. The Board found that the petitioner successfully demonstrated a rational basis for combining multiple prior art references to render the claims obvious under 35 U.S.C. § 103.
patent terminated or settled · Nov 19, 2024
Garmin International, Inc. v.Cardiacsense LTD
· IPR2025-00195
Garmin and Cardiacsense settled their IPR dispute over patent 7,980,998, leading the PTAB to terminate the proceeding without a final decision.
patent · Nov 19, 2024
Green Revolution Cooling, Inc. v.Midas Green Technologies, LLC
· IPR2025-00196
Midas Green Technologies seeks Director Review to overturn the PTAB’s decision instituting an IPR on its immersion‑cooling patent, arguing the Board misapplied Fintiv factors and recent case law.
patent · Nov 19, 2024
Digital Global Systems, Inc. v.DeepSig Inc.
· IPR2025-00194
DeepSig rebuts Digital Global Systems’ attempt to introduce new claim‑construction arguments in a PTAB Director Review request, arguing the Board’s original claim interpretations were correct and that instituting a dependent claim without an unpatentable independent claim is legally untenable.
patent terminated or settled · Nov 19, 2024
Garmin International, Inc. v.Cardiacsense LTD
· IPR2025-00195
Garmin and Cardiacsense have jointly moved to terminate their Inter Partes Review over U.S. Patent 7,980,998 after reaching a settlement. The Board is asked to dismiss the proceeding under statutory authority.
patent · Nov 19, 2024
Green Revolution Cooling, Inc. v.Midas Green Technologies, LLC
· IPR2025-00196
Green Revolution Cooling files an authorized response defending the PTAB’s institution of an IPR against Midas Green Technologies, arguing the Board correctly weighed the Fintiv factors and that petitioner’s stipulations limit prior‑art overlap.